Screener
Dianthus Therapeutics DNTH Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $627,667 | $51,087 |
| Short-term investments | 483,592 | 353,208 |
| Accounts receivable, net | 1,230 | 52 |
| Prepaid expenses and other current assets | 7,422 | 5,091 |
| Total current assets | 1,119,911 | 409,438 |
| Long-term investments | 113,868 | 110,135 |
| Property and equipment, net | 274 | 296 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's accounts receivable?
- Dianthus Therapeutics (DNTH) reported accounts receivable of $1.23M in Q1 2026.
- How has Dianthus Therapeutics's accounts receivable changed year-over-year?
- Dianthus Therapeutics's accounts receivable increased by 23.0% year-over-year, from $1M to $1.23M.
- What is the long-term trend for Dianthus Therapeutics's accounts receivable?
- Over 3 years (2022 to 2025), Dianthus Therapeutics's accounts receivable has grown at a -77.7% compound annual growth rate (CAGR), from $4.7M to $52K.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Dianthus Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude